美國伴侶動物心臟藥物市場規模、佔有率、趨勢分析報告：按藥物、動物類型、適應症、最終用途、分銷管道、細分預測，2025-2033

市場規模與趨勢：

美國伴侶動物心臟藥物市場規模預計在 2024 年為 7.7629 億美元，預計到 2033 年將達到 14.9952 億美元，2025 年至 2033 年的複合年成長率為 7.76%。推動市場發展的關鍵因素包括寵物心臟病患病率上升、寵物醫療費用增加以及研發投入增加。

例如，根據 Small Door Inc. 發表的報導，鬱血性心臟衰竭衰竭(CHF) 在狗中比較常見，影響大約 10% 的所有狗和大約 75% 患有某種心臟病的老年狗。

伴侶動物心臟病盛行率的不斷上升，正成為獸醫心臟病服務擴張的關鍵驅動力。由於獸醫護理、營養和生活方式的改善，寵物壽命延長，它們也更容易患上心血管疾病等與老齡化相關的慢性疾病。獸醫擴大診斷需要專業知識和治療的疾病，例如瓣膜疾病、心肌病和心律不整。

近年來，獸醫循環系統取得了長足進步，徹底改變了我們診斷和治療動物心臟病的方式。診斷工具、手術技術和治療方法的創新提高了護理的精準度，改善了寵物的治療效果和生活品質。例如，2025年4月，奧本大學獸醫學院為一隻名叫Hash Brown的小貓進行了一項開創性的手術，它患有上顎竇狹窄。這項混合球囊瓣環成形是世界上首例針對如此小的嬰兒患者進行的手術，由一個專家團隊通力合作完成。

創新治療方法的興起以及人們對寵物心臟健康重要性的日益重視，推動了獸醫心臟病學行業的發展。寵物飼主意識到，曾經只有人類才能獲得的延長生命療法如今已可行，因此他們正在為自己的寵物尋求專業的護理。因此，對先進獸醫循環系統服務的需求預計將持續成長，並進一步鞏固其作為現代獸醫學重要組成部分的地位。

例如，2024年6月，印度農業研究理事會發表了一項研究，調查了2022年7月至2023年9月14個月期間435只有全身性疾病史的狗的心律不整發生率。此評估旨在檢視心律不整的發生情況，其中114隻（26.21%）狗表現出各種類型的心律不整，包括心房顫動（30.70%）、ST段覆蓋、竇性停搏（各9.65%）和ST段抬高（各8.77%）。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國伴侶動物心臟藥物市場的趨勢與展望

• 市場展望
  • 母市場
  • 補貼市場
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
  • 市場機會分析
  • 市場問題分析
• 美國伴侶動物心臟藥物市場分析工具
  • 產業分析-波特五力分析
  • PESTEL分析
  • 法律規範
  • 定價分析
  • 寵物主人人口統計
  • 2024 年按國家和物種分類的寵物數量估計

第4章美國伴侶動物心臟藥物市場：藥物估計與趨勢分析

• 細分儀表板
• 美國伴侶動物心臟藥物市場：藥物變異分析
• 美國伴侶動物心臟藥物市場規模及趨勢分析（依藥物，2021-2033）
• 匹莫苯丹
• Spiranolactone和鹽酸Benazepril
• 其他

第5章美國伴侶動物心臟藥物市場：按動物類型進行的估計和趨勢分析

• 細分儀表板
• 美國伴侶動物心臟藥物市場：按動物類型分類的差異分析
• 美國伴侶動物心臟藥物市場規模及趨勢分析（以動物類型），2021-2033 年
• 狗
• 貓
• 馬
• 其他

第6章美國伴侶動物心臟藥物市場：適應症估計與趨勢分析

• 細分儀表板
• 美國伴侶動物心臟藥物市場：適應症變化分析
• 美國伴侶動物心臟藥物市場規模及趨勢分析（依適應症）（2021-2033）
• 鬱血性心臟衰竭衰竭
• 心肌疾病
• 心律不整
• 其他

第7章美國伴侶動物心臟藥物市場：最終用途估計和趨勢分析

• 細分儀表板
• 美國伴侶動物心臟藥物市場：最終用途差異分析
• 美國伴侶動物心臟藥物市場規模及趨勢分析（依最終用途），2021-2033 年
  • 獸醫診所
  • 其他

第8章美國伴侶動物心臟藥物市場：通路評估與趨勢分析

• 細分儀表板
• 美國伴侶動物心臟藥物市場：通路變化分析
• 美國伴侶動物心臟藥物市場規模及趨勢分析（按分銷管道），2021-2033 年
  • 醫院/診所藥房
  • 零售
  • 電子商務

第9章 競爭態勢

• 市場參與企業分類
• 企業市場分析/堆圖分析
• 公司簡介
  • Zoetis
  • Boehringer Ingelheim International Gmbh
  • Elanco
  • Merck &Co., Inc.
  • Dechra Pharmaceuticals PLC
  • Ceva Sante Animale
  • Phibro Animal Health Corporation
  • Virbac
  • Bimeda Corporate
  • Biogenesis Bago
• 戰略地圖
  • 合併與收購
  • 夥伴關係和合作
  • 應用程式啟動
  • 其他
• 其他主要角色列表

Market Size & Trends:

The U.S. companion animal cardiac pharmaceuticals market size was estimated at USD 776.29 million in 2024 and is projected reach USD 1,499.52 million by 2033, growing at a CAGR of 7.76% from 2025 to 2033. The key factors responsible for driving the market growth include the rising incidence of heart diseases in pets, increasing pet health expenditure, and increasing research and development.

For instance, according to an article published by Small Door Inc., Congestive heart failure (CHF) is relatively prevalent in dogs, affecting around 10% of the overall canine population and as many as 75% of older dogs who suffer from some form of heart disease.

The growing incidence of heart disease among companion animals is becoming a key driver in expanding veterinary cardiology services. As pets live longer due to general veterinary care, nutrition, and lifestyle improvements, they are more likely to develop chronic age-related conditions such as cardiovascular diseases. Veterinarians are increasingly diagnosing conditions such as valvular diseases, cardiomyopathies, and arrhythmias, which require specialized knowledge and treatment.

Veterinary cardiology has witnessed significant advancements in recent years, transforming how heart conditions in animals are diagnosed and treated. Innovations in diagnostic tools, surgical techniques, and therapeutic options are enhancing the precision of care and improving the outcomes and quality of life for pets. For instance, in April 2025, Auburn University's College of Veterinary Medicine performed a groundbreaking surgery on Hashbrown, a kitten with supravalvular mitral stenosis. This hybrid balloon valvuloplasty, a first-of-its-kind procedure for such a small and young patient, involved a collaborative effort by professionals.

The rise in innovative treatments and the increasing awareness of the importance of heart health in pets is driving growth in the veterinary cardiology industry. Pet owners increasingly seek specialized care for their animals, recognizing the availability of life-extending treatments that were once only accessible to humans. As a result, the demand for advanced veterinary cardiology services is expected to grow, further solidifying its place as a crucial component of modern veterinary medicine.

For example, in June 2024, the Indian Council for Agricultural Research published a study examining the incidence of cardiac arrhythmias in 435 dogs with a history of generalized diseases over 14 months from July 2022 to September 2023. The assessment was aimed to determine the occurrence of arrhythmias and found that 114 dogs (26.21%) displayed various types, including atrial fibrillation (30.70%), ST-segment coving, sinus arrest (9.65% each), and ST-segment elevation (8.77% each).

U.S. Companion Animal Cardiac Pharmaceuticals Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal cardiac pharmaceuticals market report based on pharmaceuticals, animal type, indication, end use, and distribution channel.

• Pharmaceuticals Outlook (Revenue, USD Million, 2021 - 2033)
• Pimobendan
• Spironolactone and Benazepril Hydrochloride
• Others
• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Horses
• Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Congestive Heart Failure
• Myocardial (Heart Muscle) Disease
• Arrhythmias
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• Others
• Distribution Channel (Revenue, USD Million, 2021 - 2033)
• Hospital/ Clinic Pharmacy
• Retail
• E-Commerce

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Cardiac Pharmaceuticals Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of heart diseases in pets
    • 3.2.1.2. Advancements in veterinary medicine
    • 3.2.1.3. Increasing research & development
    • 3.2.1.4. Increasing adoption of pet insurance
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of treatment
    • 3.2.2.2. Lack of skilled professionals
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Pricing Analysis
  • 3.3.5. Pet ownership Demographics
  • 3.3.6. Estimated pet Population by key countries, key species, 2024

Chapter 4. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Movement Analysis
• 4.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by pharmaceuticals, 2021 to 2033 (USD Million)
• 4.4. Pimobendan
  • 4.4.1. Pimobendan Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Spironolactone and benazepril hydrochloride
  • 4.5.1. Spironolactone and benazepril hydrochloride Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal type Movement Analysis
• 5.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Animal type, 2021 to 2033 (USD Million)
• 5.4. Dogs
  • 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cats
  • 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Horses
  • 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Movement Analysis
• 6.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 6.4. Congestive Heart Failure
  • 6.4.1. Congestive Heart Failure Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Myocardial (Heart Muscle) Disease
  • 6.5.1. Myocardial (Heart Muscle) Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Arrhythmias
  • 6.6.1. Arrhythmias Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Movement Analysis
• 7.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by end use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Hospitals & Clinics
    • 7.3.1.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Others
    • 7.3.2.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Movement Analysis
• 8.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 8.3.1. Hospital/ Clinic Pharmacy
    • 8.3.1.1. Hospital/ Clinic Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. Retail
    • 8.3.2.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. E-Commerce
    • 8.3.3.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heap Map Analysis
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim International Gmbh
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Elanco
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Merck & Co., Inc.
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Dechra Pharmaceuticals PLC
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Ceva Sante Animale
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Phibro Animal Health Corporation
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Virbac
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Bimeda Corporate
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Biogenesis Bago
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Application launch
  • 9.4.4. Others
• 9.5. List of other key players

List of Tables

• Table 1 List of secondary sources
• Table 2 U.S Companion Animal Cardiac Pharmaceuticals Market, by Pharmaceuticals, 2021 - 2033 (USD Million)
• Table 3 U.S Companion Animal Cardiac Pharmaceuticals Market, by Animal type, 2021 - 2033 (USD Million)
• Table 4 U.S Companion Animal Cardiac Pharmaceuticals Market, by Indication, 2021 - 2033 (USD Million)
• Table 5 U.S Companion Animal Cardiac Pharmaceuticals Market, by End Use, 2021 - 2033 (USD Million)
• Table 6 U.S Companion Animal Cardiac Pharmaceuticals Market, by Distribution Channel, 2021 - 2033 (USD Million)
• Table 7 Company Overview
• Table 8 Product Benchmarking
• Table 9 Financial Performance
• Table 10 Strategic Initiatives

List of Figures

• Fig. 1 Market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. Companion Animal Cardiac Pharmaceuticals Market revenue, 2021 - 2033 (USD Million)
• Fig. 10 U.S. Companion Animal Cardiac Pharmaceuticals Market snapshot
• Fig. 11 U.S. Companion Animal Cardiac Pharmaceuticals Market driver impact
• Fig. 12 U.S. Companion Animal Cardiac Pharmaceuticals Market restraint impact
• Fig. 13 U.S. Companion Animal Cardiac Pharmaceuticals key takeaways (USD Million)
• Fig. 14 U.S. Companion Animal Cardiac Pharmaceuticals Market: pharmaceuticals movement analysis
• Fig. 15 Pimobendan market, 2021 - 2033 (USD Million)
• Fig. 16 Spironolactone and benazepril hydrochloride market, 2021 - 2033 (USD Million)
• Fig. 17 Others market, 2021 - 2033 (USD Million)
• Fig. 18 U.S. Companion Animal Cardiac Pharmaceuticals animal type key takeaways (USD Million)
• Fig. 19 U.S. Companion Animal Cardiac Pharmaceuticals Market: animal Type movement analysis
• Fig. 20 Dogs market, 2021 - 2033 (USD Million)
• Fig. 21 Cats market, 2021 - 2033 (USD Million)
• Fig. 22 Horses market, 2021 - 2033 (USD Million)
• Fig. 23 Others market, 2021 - 2033 (USD Million)
• Fig. 24 U.S. Companion Animal Cardiac Pharmaceuticals Market Indication key takeaways (USD Million)
• Fig. 25 U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication movement analysis
• Fig. 26 Congestive Heart Failure market, 2021 - 2033 (USD Million)
• Fig. 27 Myocardial (Heart Muscle) Disease market, 2021 - 2033 (USD Million)
• Fig. 28 Arrhythmias market, 2021 - 2033 (USD Million)
• Fig. 29 Others market, 2021 - 2033 (USD Million)
• Fig. 30 U.S. Companion Animal Cardiac Pharmaceuticals Market End Use key takeaways (USD Million)
• Fig. 31 U.S. Companion Animal Cardiac Pharmaceuticals Market: End use movement analysis
• Fig. 32 Veterinary Hospitals & Clinics market, 2021 - 2033 (USD Million)
• Fig. 33 Others market, 2021 - 2033 (USD Million)
• Fig. 34 U.S. Companion Animal Cardiac Pharmaceuticals Market Distribution Channel key takeaways (USD Million)
• Fig. 35 U.S. Companion Animal Cardiac Pharmaceuticals Market: Distribution Channel movement analysis
• Fig. 36 Hospital/ Clinic Pharmacy market, 2021 - 2033 (USD Million)
• Fig. 37 Retail market, 2021 - 2033 (USD Million)
• Fig. 38 E-Commerce market, 2021 - 2033 (USD Million)
• Fig. 39 Market participant categorization